METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets prostate cancer in understudied groups
Disease control TerminatedThis study was designed to test a combination of two drugs, niraparib and abiraterone plus prednisone, in Hispanic/Latino and Black patients with a specific type of metastatic prostate cancer that has certain gene mutations. The goal was to see if the treatment could lower PSA le…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE2 • Sponsor: Qian Qin • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New study tracks heart risks of prostate cancer combo therapy
Knowledge-focused OngoingThis study observes Japanese men with metastatic hormone-sensitive prostate cancer who are already receiving darolutamide plus standard hormone therapy and chemotherapy. Researchers will collect data from regular doctor visits to monitor heart-related side effects and other safet…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 26, 2026 03:26 UTC
-
Tiny study sees if hormone pills light up hidden prostate cancer
Knowledge-focused OngoingThis early-phase study looks at whether a short course of hormone therapy can make prostate cancer cells show up brighter on PSMA PET scans. About 9 men with recurrent prostate cancer will take standard hormone pills for 4 weeks and get a scan before and after. The goal is to see…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: EARLY_PHASE1 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated May 26, 2026 03:15 UTC
-
Real-World check: does apalutamide deliver outside clinical trials?
Knowledge-focused OngoingThis study follows 170 men with metastatic hormone-sensitive prostate cancer who choose to take apalutamide as part of their normal treatment. Researchers will track PSA levels and use questionnaires to measure fatigue, thinking skills, and quality of life over two years. The goa…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated May 20, 2026 11:53 UTC
-
New scan study aims to personalize prostate cancer treatment
Knowledge-focused OngoingThis study tracks how well treatment is working in men with metastatic hormone-sensitive prostate cancer using special PET scans (PSMA-PET). Twenty participants will get a scan before starting standard therapy and another after 6 months. The goal is to see if these scans can help…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated May 15, 2026 11:58 UTC